COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Study of Bavituximab in Patients With Chronic Hepatitis C Virus Infection

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00128271
Recruitment Status : Completed
First Posted : August 9, 2005
Last Update Posted : May 7, 2008
Information provided by:
Peregrine Pharmaceuticals

Brief Summary:
The purpose of this study is to determine the safety and tolerability of bavituximab when administered via a vein as a single infusion and to examine how bavituximab behaves in the body and how it affects the amount of hepatitis C virus in individuals with chronic infection.

Condition or disease Intervention/treatment Phase
Hepatitis C Drug: Bavituximab Phase 1

Detailed Description:
Hepatitis C virus (HCV) infection is a world wide public health concern and is the most common chronic bloodborne infection in the United States and the leading indication for liver transplantation. Laboratory and animal studies have demonstrated that bavituximab binds viruses and virally infected cells and prolongs survival in infected animals. This study will examine the safety and tolerability of bavituximab when administered to patients with chronic HCV infection who do not respond to or relapse after treatment with pegylated interferon plus ribavirin combination therapy. Groups of patients will be treated with escalating doses and followed for 12 weeks.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 32 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase 1 Study of Chimeric Anti-Phosphatidylserine Monoclonal Antibody (Bavituximab) in Patients Chronically Infected With Hepatitis C Virus (HCV) Who Are Non-Responders or Relapsers After Treatment With Pegylated Interferon Plus Ribavirin
Study Start Date : August 2005
Actual Primary Completion Date : August 2006

Resource links provided by the National Library of Medicine

Primary Outcome Measures :
  1. adverse events
  2. laboratory evaluations
  3. human anti-chimeric antibody
  4. pharmacokinetic analysis
  5. viral kinetic analysis

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • At least 18 years of age
  • Chronic hepatitis C infection based on history and detectable serum HCV RNA
  • Documented failure to respond to or relapse after treatment with pegylated interferon and ribavirin combination therapy
  • Adequate hematologic function (absolute neutrophil count [ANC] greater than or equal to 1,500 cells/uL, hemoglobin [Hgb] greater than or equal to 12 g/dL in females and greater than or equal to 13 g/dL in males, platelet count greater than or equal to 100,000/uL and less than or equal to 500,000/uL)
  • Adequate renal function (serum creatinine less than or equal to 1.5 mg/dL or calculated creatinine clearance greater than 60 mL/min)
  • Normal coagulation profile (PT/INR and aPTT within institutional normal limits)
  • D-dimer within institutional limits
  • Female patients of childbearing potential must have a negative serum pregnancy test at prestudy and all patients of reproductive potential must be willing to use an approved form of barrier method contraception

Exclusion Criteria:

  • Prior exposure to any chimeric antibody
  • Any other cause of liver disease other than chronic hepatitis C, such as autoimmune or alcoholic liver disease
  • Decompensated clinical liver disease or cirrhosis
  • Any evidence of clinically significant bleeding
  • Known history of bleeding diathesis or coagulopathy
  • Any history of thromboembolic events including central venous catheter-related thrombosis
  • Any evidence or history of a hypercoagulable state (eg, elevated d-dimer or shortened aPTT)
  • Concurrent therapy with oral or parenteral anticoagulants
  • Concurrent hormone therapy (ie, estrogen contraceptives, hormone replacement, anti-estrogen)
  • Antiviral therapy within 90 days of day 0
  • Investigational therapy within 4 weeks of day 0
  • Major surgery within 4 weeks of day 0
  • Uncontrolled intercurrent disease
  • Any history of angina pectoris, coronary artery disease or cerebrovascular accident, or transient ischemic attack
  • A history of any condition requiring anti-platelet therapy with the exception of general cardiovascular prophylaxis with aspirin
  • A history of any condition requiring treatment (past or current) with coumarin-type agents
  • Cardiac arrhythmia requiring medical therapy
  • Serious non-healing wound
  • Requirement for chronic daily treatment with NSAIDs, anti-platelet drugs (eg, phosphodiesterase inhibitors, adenosine diphosphate receptor antagonists), or steroids
  • A disease or concurrent therapy known to cause significant alteration in immunologic function
  • Known HIV or active hepatitis B virus (HBV) infection

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00128271

Layout table for location information
United States, Florida
Bach & Godofsky, MD, PA
Bradenton, Florida, United States, 34205
Sponsors and Collaborators
Peregrine Pharmaceuticals
Layout table for investigator information
Principal Investigator: Eliot W Godofsky, MD, FACP Bach & Godofsky, MD, PA

Layout table for additonal information
Responsible Party: Dianne Uphoff/Senior Clinical Project Manager, Peregrine Pharmaceuticals Identifier: NCT00128271    
Other Study ID Numbers: PPHM 0501
First Posted: August 9, 2005    Key Record Dates
Last Update Posted: May 7, 2008
Last Verified: August 2006
Keywords provided by Peregrine Pharmaceuticals:
monoclonal antibody
phase 1
Additional relevant MeSH terms:
Layout table for MeSH terms
Hepatitis A
Hepatitis C
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Flaviviridae Infections
Antibodies, Monoclonal
Immunologic Factors
Physiological Effects of Drugs
Antineoplastic Agents, Immunological
Antineoplastic Agents